Proteint

About Proteint

Proteint (Tianjin) Biotechnology Co., Ltd. is a national high-tech enterprise focused on precision medicine through multi-omics research, integrating genomics, proteomics, and metabolomics. Founded in 2014 by Professor Jie Li, the company develops solutions for early screening, diagnosis, recurrence monitoring, and companion diagnostics for major cancers and cardiovascular diseases.

Dr. Li, the founder and CEO, previously held positions as a researcher at the NIH National Institute of Neurological Disorders and Stroke and at Yale University School of Medicine's Department of Pathology, where he was also director of the Yale Cancer Research Center's sample repository. He established Proteint to translate multi-omics research into clinical applications. The core team includes professionals from prominent institutions like Yale University, the US National Institutes of Health, and the National Protein Science Center.

The company's core technological approach combines genomics, proteomics, and metabolomics to provide individualized diagnostic and treatment strategies. A key technology is its proprietary n-LAPE/MS™ method for protein mass spectrometry liquid biopsy, which significantly increases the number of identifiable blood proteins. This technology is central to their product pipeline, which covers common cancers such as liver, lung, gastric, esophageal, colorectal, and pancreatic cancer. Proteint also developed the UmbrellaTM clinical molecular database, which contains data from over 100,000 clinical samples.

Proteint operates through several business segments, including diagnostics, health management, pharmaceutical services, and data services. The company has received certifications as a National High-tech Enterprise and has established a postdoctoral research workstation. It has secured multiple rounds of funding, including an Angel round in December 2021 and a Series A round of nearly 100 million RMB in January 2023, led by CDH Investments.